Klochkov, S. G.,Neganova, M. E.,Yarla, N. S.,Parvathaneni, M.,Sharma, B.,Tarasov, V. V.,Barreto, G.,Bachurin, S. O.,Ashraf, G. M.,Aliev, G.

2017

October

Semin Cancer Biolsemin Cancer Biol

Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Published

()

Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.

1096-3650 (Electronic) 10

2017/11/05

http://www.ncbi.nlm.nih.gov/pubmed/29100957http://www.ncbi.nlm.nih.gov/pubmed/29100957

10.1016/j.semcancer.2017.10.010